Integral Health Asset Management LLC Buys 250,000 Shares of Terns Pharmaceuticals, Inc. $TERN

Integral Health Asset Management LLC boosted its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) by 35.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 950,000 shares of the company’s stock after buying an additional 250,000 shares during the quarter. Integral Health Asset Management LLC’s holdings in Terns Pharmaceuticals were worth $7,134,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Engineers Gate Manager LP purchased a new position in shares of Terns Pharmaceuticals during the 2nd quarter worth about $41,000. Canada Pension Plan Investment Board bought a new stake in Terns Pharmaceuticals in the second quarter worth about $46,000. Dynamic Technology Lab Private Ltd bought a new stake in Terns Pharmaceuticals in the first quarter worth about $51,000. Velan Capital Investment Management LP boosted its position in shares of Terns Pharmaceuticals by 17.6% during the second quarter. Velan Capital Investment Management LP now owns 20,000 shares of the company’s stock valued at $75,000 after buying an additional 3,000 shares during the period. Finally, Cubist Systematic Strategies LLC raised its holdings in shares of Terns Pharmaceuticals by 136.8% in the first quarter. Cubist Systematic Strategies LLC now owns 28,327 shares of the company’s stock worth $78,000 after buying an additional 16,363 shares during the period. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Terns Pharmaceuticals Trading Up 5.2%

TERN opened at $46.52 on Friday. The company has a market capitalization of $4.83 billion, a price-to-earnings ratio of -45.17 and a beta of -0.31. Terns Pharmaceuticals, Inc. has a 12-month low of $1.87 and a 12-month high of $48.26. The business’s fifty day simple moving average is $38.76 and its 200-day simple moving average is $26.11.

Analyst Ratings Changes

TERN has been the subject of a number of recent analyst reports. Citigroup restated an “outperform” rating on shares of Terns Pharmaceuticals in a report on Wednesday, November 26th. Oppenheimer lifted their target price on Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. TD Cowen upgraded shares of Terns Pharmaceuticals to a “strong-buy” rating in a report on Friday, February 20th. Wall Street Zen raised shares of Terns Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $70.00 target price on shares of Terns Pharmaceuticals in a research note on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Terns Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $58.11.

Insider Activity

In related news, CEO Amy L. Burroughs sold 71,339 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $38.10, for a total transaction of $2,718,015.90. Following the completion of the sale, the chief executive officer directly owned 138,976 shares in the company, valued at $5,294,985.60. This represents a 33.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Emil Kuriakose sold 1,155 shares of the stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $38.57, for a total transaction of $44,548.35. Following the sale, the insider directly owned 50,365 shares of the company’s stock, valued at approximately $1,942,578.05. The trade was a 2.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 155,826 shares of company stock worth $5,882,597. 1.50% of the stock is owned by company insiders.

Terns Pharmaceuticals Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.